The World of Health & Medicine News

BrainSense brain stimulator approved for Parkinson’s patients

BrainSense brain stimulator approved for Parkinson’s patients

Medical device maker Medtronic announced Monday that the U.S. Food and Drug Administration (FDA) has approved the company’s BrainSense adaptive deep brain stimulation (aDBS) device for use in patients with Parkinson’s disease.

The approval comes just one month after Medtronic received a CE mark in Europe for a device that Medtronic designed to automatically adjust stimulation for Parkinson’s patients based on their unique brain activity to address symptoms such as involuntary tremors and balance problems.

The company also received FDA approval for the BrainSense device’s Electrode Identifier (EI). EI, also approved in Europe, provides a detailed view of the brain signals of Parkinson’s patients to help doctors better plan deep brain stimulation (DBS) and optimize treatment.

spot_img

Explore more

spot_img

US FDA approves Gilead’s twice-yearly injection for HIV prevention

US FDA approves Gilead's twice-yearly injection for HIV prevention The U.S. Food and Drug Administration on Wednesday approved Gilead Sciences (GILD.O), opens new tab lenacapavir, a twice-yearly...

WHO says ‘no evidence of harm’ from thimerosal

WHO says 'no evidence of harm' from thimerosal The World Health Organization said on Friday that thimerosal, a mercury-preservative used in some vaccines was not...

Tobacco control efforts protect 6.1 billion people – WHO’s new report

Tobacco control efforts protect 6.1 billion people – WHO’s new report The World Health Organization (WHO) today released its report on the Global Tobacco Epidemic 2025 at...

NHS makes major change to cervical cancer screenings for younger women

NHS makes major change to cervical cancer screenings for younger women Women aged 25 to 49 who test negative for human papillomavirus (HPV) will be...

Remarkable efficacy and acceptable safety of Lilly’s oral drug Orforglipron

Remarkable efficacy and acceptable safety of Lilly's oral drug Orforglipron Lilly's oral GLP-1, orforglipron, showed compelling efficacy and a safety profile consistent with injectable GLP-1...

Metsera rises as experimental weight-loss drug shows promise in small early-stage...

Metsera rises as experimental weight-loss drug shows promise in small early-stage trial Shares of weight-loss drug developer Metsera (MTSR.O), opens new tab gained as much as 25%...

Gates Foundation to commit $1.6 billion for Gavi vaccine alliance

Gates Foundation to commit $1.6 billion for Gavi vaccine alliance The Gates Foundation said on Tuesday it will commit $1.6 billion over the next five...

More than 11% weight loss with experimental drug Eloralintide in early...

More than 11% weight loss with experimental drug Eloralintide in early stages of trial Eli Lilly's experimental drug Eloralintide helps some patients lose more than...